Nanoparticles interfere with the LAL endotoxin test that is legally required before any injectable product can be released, causing both false positives and false negatives

Every injectable pharmaceutical product must pass the Limulus Amebocyte Lysate (LAL) assay for bacterial endotoxin before release — it is an FDA and EMA regulatory requirement. But nanoparticles systematically interfere with this assay in both directions. Gold nanoparticles at concentrations as low as 1 microg/mL produce a background optical density increase that registers as endotoxin (false positive). Conversely, citrate-stabilized gold colloids bind lipopolysaccharide and sequester it away from the LAL reagent, recovering less than 50% of spiked endotoxin (false negative). Titanium dioxide, silver, and iron oxide nanoparticles each exhibit their own distinct interference profiles. The consequences are severe in both directions. A false positive means a clean, safe batch gets rejected — wasting hundreds of thousands of dollars of manufactured product and delaying clinical supply. A false negative means a contaminated batch passes QC and gets injected into patients, risking sepsis, fever, or death. There is no 'safe' direction of error. For nanomedicine companies trying to file INDs or scale manufacturing, this is not an academic curiosity — it is a showstopper that can halt clinical programs. This problem persists because the LAL assay was designed in the 1970s for small-molecule drugs dissolved in clear aqueous solutions. It was never designed for turbid, particulate, optically active suspensions. The NCI Nanotechnology Characterization Laboratory (NCL) has published detailed protocols for workarounds (sample dilution, alternative chromogenic formats, recombinant Factor C assays), but these are not standardized or universally adopted. The FDA still references the LAL assay in 21 CFR 211, and switching to an alternative requires validation that many small nanotech companies cannot afford. Meanwhile, every new nanoparticle formulation potentially has a unique interference profile that must be characterized from scratch.